BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GenturaDx Announces Addition to Board of Directors


1/9/2012 12:43:51 PM

HAYWARD, Calif., Jan. 9, 2012 /PRNewswire/ -- GenturaDx today announced that its board of directors has appointed a new member, Michael Treble, who is currently chairman and CEO of Axela, Inc. The five current directors, Joe Tian of DT Capital, Min Cui of Bay City Capital, Steve Yu, company founder, Jesus Ching, co-founder and CSO, and Mark Bagnall, CEO will remain on the board.

"The addition of Mike will further diversify the talents and experience that our directors already bring to GenturaDx," said Min Cui, lead director of GenturaDx. "He is a respected and experienced business leader, and will provide our board and management team with new insight and perspectives relating to our business and company building activities."

"Mike has a proven track record of building and realizing value in emerging diagnostic companies. I look forward to working closely with him as we build GenturaDx," said Mark Bagnall, president and CEO.

About Michael Treble

Michael (Mike) Treble is currently the CEO and Chairman of Axela Biosciences, Inc. Treble was past President of Ibis BioSciences, Inc., a molecular infectious disease platform company. Ibis was acquired by Abbott Molecular Diagnostics in January 2009. Previously, Treble was President and CEO of NimbleGen Systems, Inc. Previous positions include EVP, COO and Director of Third Wave Technologies, Inc. and Marketing positions at Roche Diagnostics and Abbott Diagnostics. Treble holds a B.S. degree from Canisius College and a MBA from the University of Buffalo.

About GenturaDx

GenturaDx is a molecular diagnostic company focused on making high-performance molecular diagnostics both affordable and practical for any laboratory to perform. The company is developing a fully integrated, automated instrument that conducts testing using a single-use cassette. This platform will make rapid, high-quality molecular diagnostics accessible to hospitals and patients worldwide circumventing long-standing barriers of costs, automation and performance. GenturaDx's compact, self-contained platform incorporates sample preparation with proprietary, real-time PCR amplification and detection, reducing the risk of contamination and saving time. The platform's unique engineering design and intuitive interface relies on semi-batch processing capability while improving clinical value by offering multiple molecular targets in a single test. For more information, go to www.GenturaDx.com.

SOURCE GenturaDx



Read at BioSpace.com

GenturaDx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES